Log in

NASDAQ:RARXRa Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$47.99
0.00 (0.00 %)
(As of 04/2/2020)
Add
Compare
Today's Range
$47.99
Now: $47.99
$47.99
50-Day Range
$47.99
MA: $47.99
$48.00
52-Week Range
$19.64
Now: $47.99
$48.02
Volume30,200 shs
Average Volume1.16 million shs
Market Capitalization$2.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Ra Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.68 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$5.56 per share

Profitability

Net Income$-102,690,000.00

Miscellaneous

Employees72
Market Cap$2.27 billion
Next Earnings DateN/A
OptionableOptionable

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Ra Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ra Pharmaceuticals.

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings results on Thursday, February, 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.16. View Ra Pharmaceuticals' earnings history.

What price target have analysts set for RARX?

10 analysts have issued 1 year target prices for Ra Pharmaceuticals' stock. Their forecasts range from $48.00 to $48.00. On average, they anticipate Ra Pharmaceuticals' share price to reach $48.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Media headlines about RARX stock have trended negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Ra Pharmaceuticals.

Who are some of Ra Pharmaceuticals' key competitors?

What other stocks do shareholders of Ra Pharmaceuticals own?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the following people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 55)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
  • Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
  • Dr. Simon Read, Chief Scientific Officer (Age 48)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $47.99.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $2.27 billion and generates $3 million in revenue each year. The company earns $-102,690,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is www.rapharma.com.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.